Press Releases

EAGAN, Minn., Dec. 19, 2019 /PRNewswire/ -- The Center for Prevention at Blue Cross and Blue Shield of Minnesota has awarded nearly $2 million in funding to 15 organizations from across Minnesota as a part of the Health POWER (People Organizing and Working for Equitable R

NEW YORK, Dec. 19, 2019 /PRNewswire/ -- A successful phase III trial of anifrolumab in systemic lupus erythematosus (SLE), called TULIP-2 (Treatment of Uncontrolled Lupus via the Interferon Pathway–2), reported positive results in this week's New England Journal of Medicine (NEJM).

SHANGHAI, Dec. 19, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, convened the China Online Pharmaceuticals and Healthcare Summit 2019 (the "Summit") together with its annual general suppliers' meeting in Shanghai on Decemb

ATLANTA, Dec. 19, 2019 /PRNewswire/ -- "You have a right to know..." were the words uttered with a shaking voice by Candace Bazile's primary care physician.

BIRMINGHAM, Ala., Dec. 19, 2019 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC) today announced the appointment of three new independent directors, Greg Carmichael, Patricia Maryland, and Terrance Williams, effective January 1, 2020.&nb

DENVER, Dec. 19, 2019 /PRNewswire/ -- Leiters, a trusted FDA-registered 503B provider of high-quality compounded sterile preparations, announced today that it has entered into a national agreement with Hibernation Therapeutics to provide a patented cardioplegic solution developed by Hibernation Therapeutics known as Adenocaine™.

LEXINGTON, Mass., Dec. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in combination with balstilimab, Agenus' PD-1 inhibitor. Agenus began this study as a monotherapy in patie

HOUSTON, Dec. 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the presentation of a poster entitled, "Liposomal annamycin inhibition of lung localized breast cancer," at the San Antonio

RAMAT GAN, Israel, Dec. 19, 2019 /PRNewswire/ -- Medasense Biometrics Ltd. has been awarded a development grant from the Israel Innovation Authority (IIA) to extend the application of its NOL® pain response monitoring index for noncommunicating dementia patients. The development projec

SEATTLE, Dec. 19, 2019 /PRNewswire/ -- RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing from new and existing investors. The funding will drive a global sales expansion for its